The World Health Organization (WHO) added long-acting insulin analogues (insulin detemir, insulin degludec and insulin glargine, and their quality-assured biosimilars) to its Essential Medicines List in 2021 for the treatment of patients with type 1 or type 2 diabetes mellitus who are at high risk of experiencing hypoglycemia with human insulin [6]. The gene discussed is INS; the disease is diabetes mellitus.